Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025

Caribou Biosciences, Inc.

2025-Q2 EPS reported -$1.01 revenue$5,020,000

GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.
Cash $183.9M as of June 30, down from $249.4M at Dec 31; expected to fund operations into H2 2027.
Completed enrollment of 20-patient confirmatory cohort for CB-010 in 2L LBCL; data and pivotal trial plans expected H2 2025.
Completed dose escalation enrollment for CB-011 CaMMouflage trial in r/r MM; dose expansion data expected H2 2025.
R&D expenses fell to $27.7M from $35.5M due to pipeline prioritization and workforce reduction; G&A down to $10.4M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.